Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding
Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding Professional audiences…
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing…
Lucid Diligence Brief: NEOK Bio $75M Series A
Lucid Diligence Brief: NEOK Bio $75M Series A Professional audiences only. Not…
Lucid Diligence Brief: Evaxion $7.2m runway extension to H2 2027
Lucid Diligence Brief: Evaxion $7.2m runway extension to H2 2027 Professional…
Lucid Diligence Brief: GSK and Syndivia preclinical ADC in mCRPC
Lucid Diligence Brief: GSK and Syndivia preclinical ADC in mCRPC Professional…
Lucid Diligence Brief: Takeda and Innovent global oncology partnership
Lucid Diligence Brief: Takeda and Innovent global oncology partnership…
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics Professional…
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040 Professional…
Oncology Today: ADCs, PD-L1 & FDA Wins (Oct 6–13, 2025)
This week’s oncology highlights include breakthrough therapies such as ADCs…
Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI
Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI Professional audiences…
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close Professional…
Trending in Health Mobile Apps H1 2025
📊 Trending in Health Mobile Apps: Current Trends, Rankings and Insights from H1…